June 30, 2021: NeuroGT obtained the Exclusive License Agreement from the Office of Technology Commercialization, University of North Carolina at Chapel Hill (UNC-CH), to develop the gene therapy product NGT-102 for treating Hunter syndrome (MPS II).
June 30, 2021: NeuroGT obtained the Exclusive License Agreement from the Office of Technology Commercialization, University of North Carolina at Chapel Hill (UNC-CH), to develop the gene therapy product NGT-102 for treating Hunter syndrome (MPS II).